Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
PHVS 10.16.2024
Drug:Deucrictibant-UNKNOWN Deucrictibant
Diseases:hereditary angioedema
Date of Upcoming Event:2024-10-24
Name of Upcoming Event:American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI)
Date of Upcoming Event:2024-11-06
Name of Upcoming Event:Canadian Society of Allergy and Clinical Immunology (CSACI)
Date of Upcoming Event:2024-10-18
Name of Upcoming Event:Japanese Society of Allergology (JSA)
About Gravity Analytica
Recent News
- 02.12.2025 - February 12, 2025 9:20 AM EST - February 12, 2025 9:50 AM EST : Oppenheimer 35th Annual Healthcare Life Sciences Conference
- 01.15.2025 - January 15, 2025 8:15 AM EST - January 15, 2025 8:55 AM EST : 43rd Annual J.P. Morgan Healthcare Conference
- 01.13.2025 - Pharvaris Outlines 2025 Strategic Priorities
Recent Filings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) --Pharvaris(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:
American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI),Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:
- Poster:Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension StudySpeaker:John Anderson, M.D.Format:e-Poster (R102)Date, Time:Friday, Oct. 25, 2:00-2:15 p.m. EDTLocation:Monitor 21, Exhibit Hall A
- Poster:Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study ResultsSpeaker:John Anderson, M.D.Format:e-Poster (R103)Date, Time:Friday, Oct. 25, 2:15-2:30 p.m. EDTLocation:Monitor 21, Exhibit Hall A
- Poster:Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated DisordersSpeaker:Evangelia Pardali, Ph.D.Format:e-Poster (R088)Date, Time:Friday, Oct. 25, 2:30-2:45 p.m. EDTLocation:Monitor 20, Exhibit Hall A
- Poster:Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated DisordersSpeaker:Evangelia Pardali, Ph.D.Format:e-Poster (R090)Date, Time:Friday, Oct. 25, 3:00-3:15 p.m. EDTLocation:Monitor 20, Exhibit Hall A
- Poster:The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in HumansSpeaker:Juan Bravo, Ph.D.Format:e-Poster (R112)Date, Time:Friday, Oct. 25, 4:30-4:45 p.m. EDTLocation:Monitor 21, Exhibit Hall A
- Poster:CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema ProphylaxisSpeaker:H. James Wedner, M.D.Format:e-Poster (R100)Date, time:Friday, Oct. 25, 5:30-5:45 p.m. EDTLocation:Monitor 20, Exhibit Hall A
- Poster:Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of LifeSpeaker:H. James Wedner, M.D.Format:e-Poster (R101)Date, Time:Friday, Oct. 25, 5:45-6:00 p.m. EDTLocation:Monitor 20, Exhibit Hall A
Canadian Society of Allergy and Clinical Immunology (CSACI),Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.
- Poster:Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 TrialSpeaker:William H. Yang, M.D., FRCPC, FAAAAIFormat:PosterDate, Time:Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
- Poster:Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study resultsSpeaker:William H. Yang, M.D., FRCPC, FAAAAIFormat:PosterDate, Time:Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
- Poster:Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study resultsSpeaker:Hugo Chapdelaine, M.D., FRCPCFormat:PosterDate, Time:Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
Japanese Society of Allergology (JSA),Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation.
- Presentation:Efficacy and safety of oral deucrictibant IR capsule in HAE: RAPIDe-3 phase 3 trial designSpeaker:Prof. Michihiro Hide, M.D., Ph.D.Format:Oral PresentationDate, Time:Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT)
The presentation slides and posters will be available on the Investors section of the Pharvaris website at:https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visithttps://pharvaris.com/.
ContactMaggie BellerExecutive Director, Head of Corporate and Investor Communicationsmaggie.beller@pharvaris.com